Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Directors of five NIH institutes have been placed on administrative leave or offered new assignments as part of sweeping HHS ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...